XML 74 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
AstraZeneca | Other current assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from counterparty $ 215 $ 128  
AstraZeneca | Accrued and other current liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 423 577  
AstraZeneca | Total sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Total sales 733 444 $ 187
AstraZeneca | Total sales | Alliance revenue - Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Total sales 725 444 187
AstraZeneca | Total sales | Alliance revenue - Koselugo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Total sales 8 0 0
AstraZeneca | Cost of sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 247 148 93
AstraZeneca | Selling, general and administrative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 160 138 48
AstraZeneca | Research and development      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 133 168 152
Eisai | Other current assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from counterparty 157 150  
Eisai | Accrued and other current liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 335 700  
Eisai | Other Noncurrent Liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 600 525  
Eisai | Total sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Total sales 580 404 149
Eisai | Cost of sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 271 206 39
Eisai | Selling, general and administrative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 73 80 13
Eisai | Research and development      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 185 189 1,489
Bayer AG | Other current assets      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables from counterparty 65 49  
Bayer AG | Other Noncurrent Liabilities      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables to counterparty 0 375  
Bayer AG | Total sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales of Adempas recorded by Merck 220 215 190
Merck’s profit share of sales in marketing territories 281 204 139
Total sales 501 419 329
Bayer AG | Cost of sales      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 115 113 216
Bayer AG | Selling, general and administrative      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses 61 41 35
Bayer AG | Research and development      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Expenses $ 63 $ 126 $ 127